PERFORMANCE MONITORING FOR ACTION

PMA NIGERIA (LAGOS)

Results from Phase 4 Cross-sectional Survey

December 2023 - February 2024

OVERALL KEY FINDINGS

Contraceptive use among all women has increased by 9 percentage points over the 8 year period of observation, from 17% in 2015 to 26% in 2024.

PMA NIGERIA

While condoms have consistently been the most frequently used method, the percentage of women reporting use of implants has increased from 1% in 2015 (R1) to 20% in 2024 (P4), becoming the second most frequently reported modern method.




Stockouts of implants in public facilities were reported to be in the double digits on the day of the most recent survey.

SECTION 1: CONTRACEPTIVE USE, DYNAMICS, AND DEMAND

TRENDS IN MODERN CONTRACEPTIVE MIX

Percent distribution of all women age 15-49 using modern contraceptive methods by method and year (PMA Phase 4 n=331)








(CRERD



FAMILY PLANNING








Page 2

PMANIGERIA




INTENTION OF MOST 24% **RECENT BIRTH/CURRENT** PREGNANCY of pregnancies were unintended Percent of women by intention of their most recent birth or current pregnancy (n=353) 7% Wanted no more 17% children Wanted later 76% Intended

KEY FINDINGS FOR SECTION 1: CONTRACEPTIVE USE, DYNAMICS, AND DEMAND

- In the 2024 (P4) survey, 26% of all women ages 15-49 years reported using a modern method, and 52% of demand was satisfied by a modern method.
- Following the steady rise in modern contraceptive use among all women observed between R3 and P1, the curve appears to have flattened.
- Traditional method use appeared to increase steadily from R1 until P2, but now appears to be on a downward trend.
- The most reported method among all women since R1 was the male condom. Implant use has risen steadily and is now the second most reported method.
- Among all women who were not currently using contraception,
 4% said they intend to use a method in the 12-month period
 following the survey.
- 24% of pregnancies were reported as unintended.

SECTION 2: CONTRACEPTIVE USER COUNSELING AND OUTREACH




SECTION 3: PARTNER DYNAMICS


PARTNER INVOLVEMENT IN FP DECISIONS

Percent of women who are currently using modern, female controlled methods and agree with the following statement, by age and education (n=189)







Percent of women who are currently using modern, female controlled methods and agree with the following statement, by age and education (n=483)
Mainly respondent



Percent of women who are currently using modern, female controlled methods and agree with the following statement, by age and education (n=188)



Percent of women who are not currently using modern, female controlled methods and agree with the following statement, by age and education (n=673)




KEY FINDINGS FOR SECTION 3: PARTNER DYNAMICS


- Among women using a modern, female controlled method, 15% reported that their partners were unaware that they were using a method, with variations by age and educational level.
- Among women using a modern, female controlled method, 72% reported that using family planning was mainly a joint decision.
- Among women using a modern, female controlled method, 28% reported that not using family planning was mainly a joint decision.
- 21% of women using modern, female controlled methods reported that they had not discussed the decision to delay or avoid pregnancy with their partner prior to using their current method, with variations by age and level of education.

Page 5


SECTION 4: SERVICE DELIVERY POINTS




TRENDS IN METHOD AVAILABILITY: IMPLANT Public Facilities (PMA Phase 4 n=77)




Private Facilities (PMA Phase 4 n=48)



In Stock In Stock, but stockout in last 3 months Out of Stock On 't offer method





Page 7

PMANIGERIA

35%

of women obtained their current

modern method from a public health facility (n=323)

KEY FINDINGS FOR SECTION 4: SERVICE DELIVERY POINTS

- IUDs have been reported to be offered and in stock on the day of the survey by 79% or more of public facilities, but only 21% or less of private facilities across all the annual surveys.
- Implants, the second most reported contraceptive method were out-of-stock in 18% of public facilities during the most recent phase of data collection (P4). Furthermore, while in stock on the day of the survey, implants had been stocked out in another 18% of public facilities in the 3-month period preceding the survey. Implants were offered and in-stock in only 1 in 10 private facilities visited in the most recent survey (P4).
- Injectables and oral pills were stocked out in 13% and 10% of private facilities respectively on the day of the most recent survey in 2023. The main reason given for episodes of stockout of any method in private facilities was that they did not place an order for shipment.
- 75% and 68% of facilities showed readiness for provision and removal of implants and IUDs respectively.

TABLE: CONTRACEPTIVE PREVALENCE AND UNMET NEED

	ALL WOMEN	CPR				mCPR				Unmet need for family planning				
Data source	Round/ Data Phase collection	Female sample	CPR%	SE	95%	S CI	mCPR%	SE	95%	S CI	Unmet need (%)	SE	95%	6 CI
РМА 2020	Round 1 Sept-Oct 2014	764	18.11	1.64	15.03	21.67	16.72	1.54	13.83	20.07	19.18	1.58	16.18	22.58
РМА 2020	Round 2 Oct-Nov 2015	1429	27.78	1.87	24.19	31.68	21.03	1.42	18.33	24.01	17.83	1.44	15.13	20.90
РМА 2020	Round 3 May-Jul 2016	1432	26.42	1.86	22.87	30.30	19.68	1.19	17.41	22.18	15.60	1.43	12.95	18.68
РМА 2020	Round 4 Apr-May 2017	1535	29.72	2.22	25.47	34.36	20.55	1.59	17.55	23.93	15.17	1.19	12.94	17.71
РМА 2020	Round 5 Apr-Jun 2018	1590	33.14	1.85	29.54	36.94	22.66	1.50	19.80	25.80	12.32	0.95	10.54	14.36
PMA	Phase 1 Nov-Jan 2020	1469	38.17	1.48	35.25	41.17	25.63	1.16	23.38	28.02	10.77	1.12	8.72	13.23
PMA	Phase 2 Dec-Feb 2021	1483	40.12	1.87	36.44	43.93	24.23	1.23	21.85	26.79	10.57	1.15	8.47	13.11
PMA	Phase 3 Dec-Jan 2022	1426	41.03	1.94	37.21	44.96	26.72	1.57	23.69	29.98	8.44	0.86	6.86	10.33
PMA	Phase 4 Dec-Feb 2024	1250	38.82	2.37	34.20	43.66	25.62	1.68	22.41	29.13	10.75	1.20	8.58	13.4

WOMEN	CPR				mCPR				Unmet need for family planning					
Data Round source Phase	[/] Data F collection s	Female sample	CPR%	SE	95%	CI	mCPR%	SE	95%	CI	Unmet need (%)	SE	95%	CI
PMA Round 1 2020	Sept-Oct 4 2014	490	21.26	2.16	17.22	25.97	19.74	2.08	15.87	24.28	26.76	2.06	22.81	31.13
PMA Round 2 2020	Oct-Nov g 2015	951	34.63	2.54	29.72	39.89	26.36	1.93	22.67	30.41	23.70	1.73	20.41	27.33
PMA Round 3 2020	May-Jul 8 2016	383	32.50	2.39	27.90	37.47	22.92	1.71	19.68	26.53	21.47	1.88	17.95	25.47
PMA Round 4 2020	Apr-May <u>1</u> 2017	1001	35.88	2.53	30.97	41.10	23.31	1.75	20.00	26.99	20.86	1.64	17.76	24.35
PMA Round 5 2020	Apr-Jun g 2018	978	40.29	2.68	35.06	45.76	25.53	2.09	21.57	29.94	17.72	1.29	15.28	20.46
PMA Phase1	Nov-Jan 2020 8	877	46.53	2.22	42.12	50.99	28.82	1.81	25.33	32.59	15.38	1.67	12.32	19.02
PMA Phase 2	Dec-Feb 8 2021	855	52.66	2.61	47.42	57.83	30.80	1.96	27.02	34.87	15.00	1.58	12.10	18.45
PMA Phase 3	Dec-Jan 8 2022	805	53.33	2.49	48.33	58.27	32.06	1.97	28.24	36.12	13.44	1.55	10.62	16.85
PMA Phase 4	Dec-Feb 7 2024	701	52.93	3.02	46.87	58.89	32.79	2.06	28.80	37.05	16.82	2.31	12.70	21.94

PMA Nigeria (Lagos) collects information on knowledge, practice, and coverage of family planning services in 52 enumeration areas selected using a multi-stage stratified cluster design. The results are representative at the state-level. Phase 4 data were collected between December 2023 and January 2024 from 1495 households (92.5% response rate), 1250 females age 15-49 (95.3% response rate), and 135 facilities (83.9% completion rate). For sampling information and full data sets, visit www.pmadata.org/countries/nigeria

Percentages presented in this brief have been rounded and may not add up to 100%.

PMA uses mobile technology and female resident data collectors to support rapid-turnaround surveys to monitor key family planning and health indicators in Africa and Asia. PMA Nigeria is led by the Centre for Research, Evaluation Resources and Development (CRERD). Overall direction and support are provided by the Bill & Melinda Gates Institute for Population and Reproductive Health at The Johns Hopkins University and Jhpiego. Funding is provided by the Bill & Melinda Gates Foundation.